{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:50:20Z","timestamp":1791931820105,"version":"4.3.4"},"reference-count":33,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2026,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The investigation of peripheral neurotoxicity associated with systemic anticancer therapy (SACT) agents is often confined to a small range of chemotherapy agents. This study aimed to identify all SACT agents associated with peripheral neurotoxicity and, specifically, peripheral neuropathy, and to provide incidence estimates for the development of each type of neurotoxicity associated with each agent. Antineoplastic agents approved globally for clinical and\/or research purposes were identified through triangulation of nine national and global drug product databases. The class of each agent was identified using DrugBank Online. Evidence of peripheral neurotoxicity and, specifically, peripheral neuropathy was obtained by reviewing Micromedex (and, where required, supplemented by data reported in national clinical trials registries). A total of 467 approved antineoplastic agents were identified for clinical and\/or research purposes globally. Peripheral neurotoxicity (including neuropathy) was associated with 144 (31%) agents: 49 (45%) classical chemotherapeutic agents; 61 (21%) targeted therapies; 26 (63%) immunotherapies; and 8 (25%) hormone therapies. Peripheral neuropathy, specifically, was associated with 77 (16%) agents: 30 (27%) classical chemotherapeutic agents; 31 (11%) targeted therapies; 16 (39%) immunotherapies; and no hormone therapies. Based on the currently available evidence, this inventory of neurotoxic SACT agents could be considered exhaustive. From clinical and research perspectives, a comprehensive inventory of neurotoxic SACT agents is pivotal to informing drug design and understanding and implementing appropriate drug choice, as well as investigating the mechanisms involved in the neurotoxic effects of agents and identifying neuroprotective strategies for patients undergoing SACT.<\/jats:p>","DOI":"10.1002\/ijc.70414","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T10:06:18Z","timestamp":1772964378000},"page":"460-466","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Systemic anti\u2010cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy"],"prefix":"10.1002","volume":"159","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5506-324X","authenticated-orcid":false,"given":"Cassie","family":"Higgins","sequence":"first","affiliation":[{"name":"Division of Population Health and Genomics School of Medicine, University of Dundee, Mailbox 1, Level 7, Corridor L, Ninewells Hospital  Dundee UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn R.","family":"Gauthier","sequence":"additional","affiliation":[{"name":"Department of Family and Emergency Medicine, Faculty of Medicine Universit\u00e9 Laval; Centre de Recherche du CHU de Qu\u00e9bec\u2010Universit\u00e9 Laval, Centre int\u00e9gr\u00e9 de canc\u00e9rologie, CHU de Qu\u00e9bec\u2010Universit\u00e9 Laval  Qu\u00e9bec City Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blair H.","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Population Health and Genomics School of Medicine, University of Dundee, Mailbox 1, Level 7, Corridor L, Ninewells Hospital  Dundee UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Colvin","sequence":"additional","affiliation":[{"name":"Division of Population Health and Genomics School of Medicine, University of Dundee, Mailbox 1, Level 7, Corridor L, Ninewells Hospital  Dundee UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2014.09.020"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-021-00168-y"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.750507"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.626687"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2017.00397"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2021.1954241"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020888"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061451"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000040649"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1268672"},{"issue":"1","key":"e_1_2_10_12_1","article-title":"Aromatase inhibitors evoke periorbital allodynia in mice via calcitonin gene\u2010related peptide and its receptors in schwann cells","volume":"34","author":"Marini M","year":"2024","journal-title":"Conf Cephalalgica"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0000000000001073"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-023-01315-w"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4259205"},{"key":"e_1_2_10_16_1","volume-title":"Anatomy, head and neck: blood brain barrier","author":"Dotiwala AK","year":"2024"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24951"},{"key":"e_1_2_10_18_1","unstructured":"Association of the British Pharmaceutical Industry.Global rankings \u2013 number of industry clinical trials initiated in 2021 by country by phase.2023https:\/\/www.abpi.org.uk\/facts\u2010figures\u2010and\u2010industry\u2010data\/clinical\u2010trials\/global\u2010data\/global\u2010rankings\u2010number\u2010of\u2010industry\u2010clinical\u2010trials\u2010initiated\u2010in\u20102021\u2010by\u2010country\u2010by\u2010phase\/. Accessed 9 December 2024"},{"key":"e_1_2_10_19_1","unstructured":"National Institutes of Health National Cancer Institute.Types of cancer treatment.2025https:\/\/www.cancer.gov\/about-cancer\/treatment\/types. Accessed 25 January 2025"},{"key":"e_1_2_10_20_1","unstructured":"American Cancer Society.Chemotherapy.2025https:\/\/www.cancer.org\/cancer\/managing\u2010cancer\/treatment\u2010types\/chemotherapy.html. Accessed 25 January 2025"},{"key":"e_1_2_10_21_1","unstructured":"Government of Canada: Health Canada.Drug Product Database.2025https:\/\/health-products.canada.ca\/dpd-bdpp\/. Accessed 16 July 2025"},{"key":"e_1_2_10_22_1","unstructured":"European Medicines Agency.Download medicine data.2025https:\/\/www.ema.europa.eu\/en\/medicines\/download-medicine-data. Accessed 25 January 2025"},{"key":"e_1_2_10_23_1","unstructured":"Cancer Research UK.Cancer drugs A to Z list.2025https:\/\/www.cancerresearchuk.org\/about-cancer\/treatment\/drugs. Accessed 25 January 2025"},{"key":"e_1_2_10_24_1","unstructured":"National Cancer Centre Hospital Japan.\u304c\u3093\u7a2e\u5225\u5316\u5b66\u7642\u6cd5\u306b\u3064\u3044\u3066 \u4f7f\u7528\u85ac\u5264\u3068\u305d\u306e\u526f\u4f5c\u7528 [translation: About chemotherapy by cancer type drugs used and their side effects].2025https:\/\/www.ncc.go.jp\/jp\/ncch\/division\/pharmacy\/010\/pamph\/index.html. Accessed 1 March 2025"},{"key":"e_1_2_10_25_1","unstructured":"eviQ NSW Government.Medical oncology.2025https:\/\/www.eviq.org.au\/medical-oncology. Accessed 18 February 2025"},{"key":"e_1_2_10_26_1","unstructured":"World Health Organization.Norwegian Institute of Public Health: Antineoplastic agents.2025https:\/\/atcddd.fhi.no\/atc_ddd_index\/?code=L&showdescript. Accessed 25 January 2025"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.627574"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkad976"},{"key":"e_1_2_10_29_1","unstructured":"Micromedex\u00ae (electronic version).Merative Ann Arbor Michigan USA.https:\/\/www.micromedexsolutions.com\/. Accessed 24 January 2025"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-317215"},{"key":"e_1_2_10_31_1","unstructured":"HealyM.Neurotoxicity. OncoLink information resource.2024https:\/\/www.oncolink.org\/support\/side\u2010effects\/neurological\u2010side\u2010effects\/neurotoxicity. Accessed 9 December 2024"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-016-0686-x"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363150-00003"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00152-2"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.70414","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ijc.70414","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.70414","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:14:06Z","timestamp":1779376446000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.70414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,7,15]]}},"alternative-id":["10.1002\/ijc.70414"],"URL":"https:\/\/doi.org\/10.1002\/ijc.70414","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"assertion":[{"value":"2025-09-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}